Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 9, 2002

DEVICE USES ENGINEERED PROTEIN TO TREAT BACK DISORDER

9 JULY - FDA has approved the first device that uses a genetically engineered human protein for use in the lower region of the spine to treat degenerative disc disease, a major cause of back pain for many adults.

DEVICE USES ENGINEERED PROTEIN TO TREAT BACKDISORDER -- FDA has approved the first device that uses agenetically engineered human protein for use in the lower regionof the spine to treat degenerative disc disease, a major cause ofback pain for many adults.http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01155.html


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.